Frequency and absolute numbers of circulating CD56+/Siglec-7+, CD56−/Siglec-7+, and CD56−/Siglec-7− NK-cell subsets from HIV-1–infected patients at different stages of disease compared with those from healthy donors
| Cohort . | NK cells . | |||
|---|---|---|---|---|
| CD56+/Siglec-7+ . | CD56+/Siglec-7− . | CD56−/Siglec-7− . | Total . | |
| Healthy donors (n = 70) | 11.1 ± 4.3 (190 ± 64) | 1.1 ± 1.3 (20 ± 15) | 0.8 ± 0.6 (14 ± 20) | 13.3 ± 6.1 (223 ± 91) |
| Early HIV-1 infection (n = 21) | 6.5 ± 3.3 (108 ± 71, ↓)* | 7.5 ± 3.6 (125 ± 62, ↑)* | 1.4 ± 0.9 (23 ± 19, ∼)† | 15.6 ± 12.3 (258 ± 146, ∼)† |
| Chronic viremic HIV-1 infection (n = 96) | 3 ± 2.1 (49 ± 25, ↓)* | 5.7 ± 3.1 (98 ± 32, ↑)* | 5.1 ± 2.1 (82 ± 38, ↑)* | 14.1 ± 5.6 (231 ± 73, ∼)† |
| Chronic LTNPs (n = 27) | 10.9 ± 4.8 (185 ± 46, ∼)† | 1.74 ± 1.5 (32 ± 25, ∼)† | 1.3 ± 1.1 (25 ± 16, ∼)† | 14.3 ± 6.1 (245 ± 85, ∼)† |
| Cohort . | NK cells . | |||
|---|---|---|---|---|
| CD56+/Siglec-7+ . | CD56+/Siglec-7− . | CD56−/Siglec-7− . | Total . | |
| Healthy donors (n = 70) | 11.1 ± 4.3 (190 ± 64) | 1.1 ± 1.3 (20 ± 15) | 0.8 ± 0.6 (14 ± 20) | 13.3 ± 6.1 (223 ± 91) |
| Early HIV-1 infection (n = 21) | 6.5 ± 3.3 (108 ± 71, ↓)* | 7.5 ± 3.6 (125 ± 62, ↑)* | 1.4 ± 0.9 (23 ± 19, ∼)† | 15.6 ± 12.3 (258 ± 146, ∼)† |
| Chronic viremic HIV-1 infection (n = 96) | 3 ± 2.1 (49 ± 25, ↓)* | 5.7 ± 3.1 (98 ± 32, ↑)* | 5.1 ± 2.1 (82 ± 38, ↑)* | 14.1 ± 5.6 (231 ± 73, ∼)† |
| Chronic LTNPs (n = 27) | 10.9 ± 4.8 (185 ± 46, ∼)† | 1.74 ± 1.5 (32 ± 25, ∼)† | 1.3 ± 1.1 (25 ± 16, ∼)† | 14.3 ± 6.1 (245 ± 85, ∼)† |
Results include the percentages of CD3−/CD19−/CD14− NK-cell subsets within the lymphocyte population, followed by the absolute numbers of cells/μL (values in parentheses), presented as median ± SD. See also Figure 1 for gating strategy.
↑ indicates increased; ↓, decreased; and ∼, stable.
P < .001.
P = not significant.